RxDoctor Payments Data

Megan Colburn

Gerontology · Tumwater, WANPI 1922482074

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 24.2% of the total.

$487in general payments, 2019–2025

Across 14 payments — averaging $34.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$118
  • Amgen$112
  • Boehringer Ingelheim$53
  • Novo Nordisk$44
  • Dexcom, Inc.$40
  • Abbott$30
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$45794%
  • Other$306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 65th percentile of 105 gerontology providers in Washington.

See all gerontology providers in Washington

Medicare billing

Part B allowed, 2024
$7,830
Medicare patients
145
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$41,940
JardianceEmpagliflozin30$35,582
TrulicityDulaglutide21$25,074
EliquisApixaban27$22,494
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,699
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,290
Levothyroxine Sodium141$2,420
Atorvastatin Calcium187$2,252
Gabapentin92$1,857
Bupropion XlBupropion Hcl24$1,818
Albuterol Sulfate HfaAlbuterol Sulfate56$1,739
Losartan Potassium144$1,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,537
Omeprazole91$1,239
Metoprolol Succinate68$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$41,94036 claims
Boehringer IngelheimJardiance, Stiolto Respimat$53$40,87241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 105 gerontology providers in Washington.

Other gerontology in Tumwater

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →